Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VOLITE XC, VOLITE XC · 1 trial · 1 indication
ATNLS is a 5-point photonumeric scale to grade the severity of transverse neck lines (0=None, 4=Extreme). A "responder" is a participant with at least 1-grade improvement on the ATNLS.
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
| Arm | Type | Description |
|---|---|---|
| VOLITE XC | EXPERIMENTAL | Participants will receive VOLITE XC for initial treatment and followed for up to 14 Months. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of VOLITE XC during the follow-up duration period. |
| Control Group | OTHER | The control group received no treatment and will be followed for up to 6 months after randomization. Participants can then opt to receive VOLITE XC and followed for 6 Months. |
| Name | Type | Description |
|---|---|---|
| VOLITE XC | DEVICE | Intradermal Injection |
Inclusion Criteria: * Participants in general good health as determined by Treating Investigator's judgment, including no known active pandemic infection. * Participants seeking improvement of transverse neck lines. * Has moderate or severe transverse neck lines (ATNLS Grade 2 or 3) based on EI liv...
VOLITE XC is an injectable gel used for the improvement of neck appearance, specifically targeting neck lines. It is being developed by AbbVie Inc. for use in dermatology. The product is currently in Phase 3 clinical development for this indication.
VOLITE XC is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The product is intended for the improvement of neck lines and is currently in Phase 3 clinical development.
VOLITE XC is in Phase 3 clinical development. It is an investigational product being studied for the improvement of neck lines. A Phase 3 clinical trial has been completed to evaluate its safety and effectiveness for this indication.
VOLITE XC has been studied in a Phase 3 clinical trial with the identifier NCT05316233, titled 'JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck Appearance.' This trial was completed and enrolled 159 participants in the United States.
Yes, VOLITE XC is also known as JUVÉDERM® VOLITE™ XC. The clinical trial for this product is titled 'JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck Appearance,' confirming that VOLITE XC is part of the JUVÉDERM family of products.